---
run_id: halo-evidence-vs-diagnosis-validation-v10-vanilla-03
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: vanilla
run_number: 3
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 301
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
condition_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
output_file: model-outputs/vanilla-03.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 03)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `vanilla`, run 3 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 301, on the frozen condition packet.

## Output

I recommend the **Claim File Review**.

### The Recommendation
You should advise the CEO to commit to the Claim File Review. While your current metrics (expansion bookings, usage percentages) look strong on a dashboard, they are "noisy" and potentially deceptive. You have a classic discrepancy between **perceived value** (Sales/Executive view) and **actual utility** (User view).

The Claim File Review is the only option that solves for the "truth" of the product's efficacy. By auditing actual claim files, you move past vanity usage (managers rerunning samples) and surface-level enthusiasm (bundle-driven renewals). You will discover if DraftPath is actually solving the core problem or if it is simply a "manager's tool" that adjusters find cumbersome or inexplicable. This provides the necessary evidence to decide whether to scale, pivot for health-liability, or rebuild the core logic before the budget is locked.

### The Strongest Reason Against It
The Claim File Review provides **lagging, qualitative data** rather than leading, quantitative data. Unlike the Usage Quality Sprint (which tracks real-time behavior) or the Commercial Cleanroom (which tests immediate price elasticity), a file review is slow and manual. It tells you *what happened* in the past, but it does not instantly prove that fixing a specific friction point will stop the regional carriers from churning or increase the expansion rate in the next quarter.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the regional carriers planning to remove DraftPath are not complaining about *utility* (the "what"), but rather about *value/pricing* (the "how much").

If the account managers report that those carriers love the feature but find the price point unjustifiable regardless of the "bundle" incentive, your problem is a pricing/packaging failure, not a product-market fit failure. In that specific scenario, the Claim File Review is a waste of time because the product works; you simply haven't found the right commercial model.
